Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?
Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?
复制标题
DOI：
10.1016/j.juro.2006.08.070
复制
发表时间：
2007-01-01
影响因子：
6.6
通讯作者：
Dalbagni, Guido
中科院分区：
文献类型：
--
作者：
Herr, Harry W.;Donat, S. Machele;Dalbagni, Guido
目的：我们确定是否再分期经尿道切除术的病理结果预测T1膀胱cancer.Materials和方法的早期进展：一个队列的352例T1膀胱癌初次经尿道切除术进行了评估，第二次或再分期经尿道切除术。所有患者均接受卡介苗治疗，88%的患者随访5年。再分期经尿道切除术的病理结果与肿瘤的特点，阶段进展的频率和无进展survival.Results：352例T1肿瘤203（58%）有残留的肿瘤再分期经尿道切除术，其中92（26%）与残留的非肌层浸润性（T1）癌。在5年期间，66%的病例复发，35%的病例分期进展。残留T1癌的92例患者75（82%）进展到肌肉浸润5年内相比，49 260（19%）谁没有或nonT1肿瘤检测到的再分期经尿道切除术。结论：再分期经尿道切除术确定T1膀胱癌患者谁是在早期肿瘤进展的高风险，证明立即cycerythema。
Purpose: We determined whether pathological findings on restaging transurethral resection predict early stage progression of T1 bladder cancer.Materials and Methods: A cohort of 352 patients presenting with T1 bladder cancer on initial transurethral resection was evaluated by second or restaging transurethral resection. All patients received bacillus Calmette-Guerin therapy and 88% were followed for 5 years. Pathological findings on restaging transurethral resection were correlated with tumor features, stage progression frequency and progression-free survival.Results: Of the 352 patients with T1 tumors 203 (58%) had residual tumor on restaging transurethral resection, including 92 (26%) with residual nonmuscle invasive (T1) cancer. During 5 years 66% of cases recurred and 35% progressed in stage. Of the 92 patients with residual T1 cancer 75 (82%) progressed to muscle invasion within 5 years compared to 49 of 260 (19%) who had no or nonT1 tumor detected on restaging transurethral resection.Conclusions: Restaging transurethral resection identifies patients with T1 bladder cancer who are at high risk for early tumor progression, justifying immediate cystectomy.